



29 January 2026

Sydney, Australia

Update to Nyrada Substantial Holders

Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, advises of changes to its substantial holder balances.

The Company has been notified that Mr Mark Azzi has disposed of 20,200,000 Nyrada CHES Depository Interests ("CDIs") due to an urgent personal circumstance. The disposal was by way of a series of off-market transfers. Of the CDIs disposed:

- 14,000,000 CDIs were acquired by Matt Corp WA Pty Ltd and associated parties; and
- the remaining 6,200,000 CDIs were acquired by unrelated third-party investors (new and existing).

Mr Azzi has further advised Nyrada that he continues to maintain his long-term support for the Company and has indicated to the Company that he does not intend to dispose of any further Nyrada securities.

In accordance with the Deed Poll dated 6 January 2020 issued by Nyrada in favour of ASX Limited in connection with Nyrada's initial public offering, the Company is required to notify the market of changes to its substantial holders and will continue to do so as required.

-ENDS-

For personal use only



About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.